Structural, biophysical, and virological mechanistic characterization of HIV-1 capsid-targeting antivirals
Kirby, K. A.; McFadden, W. M.; Wang, L.; Du, H.; Zhang, H.; Emanuelli Castaner, A.; Lorson, Z. C.; Nafisi, A.; Luchsinger, C.; Hachiya, A.; Cilento, M. E.; Snyder, A. A.; Ravichandran, S. M.; Cai, X.; Tedbury, P. R.; Francis, A. C.; Melikyan, G. B.; Diaz-Griffero, PhD, F. R.; Wang, Z.; Sarafianos, S. G.
Show abstract
Due to its significant role in virus replication, the HIV capsid is an attractive antiviral target. This is validated by the recent clinical approval of lenacapavir for both treatment and pre-exposure prophylaxis (PrEP). PF74 is a well-characterized capsid-targeting antiviral that was discontinued in further study due to potency and metabolic issues. We hypothesized that making chemical modifications at certain sites of PF74 could result in capsid-targeting antivirals with improved potency and bioavailability. Our cumulative studies show that making changes at the R1 and R3 positions of PF74 results in compounds with increased antiviral potency, increased stability of wild-type HIV capsid hexamers and virions, tighter binding to wild-type HIV capsid hexamer compared to PF74, and different interactions at the "FG" binding site of capsid compared to PF74. These data provide insights into the design of future capsid-targeting antivirals relevant for clinical use.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Small molecule inhibitors of transcriptional Cyclin Dependent Kinases impose HIV-1 latency, presenting "block and lock" treatment strategies 96%
- Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants 96%
- Selective estrogen receptor modulators limit alphavirus infection by targeting the viral capping enzyme nsP1 96%
Similar papers in this journal
- Mechanism and spectrum of inhibition of a 4'-cyano modified nucleotide analog against diverse RNA polymerases of prototypic respiratory RNA viruses 95%
- A heterocyclic compound inhibits viral release by inducing cell surface BST2/Tetherin/CD317/HM1.24 95%
- Structural basis for Nirmatrelvir in vitro efficacy against SARS-CoV-2 variants 95%
Similar papers in this journal
- Identification of an antiretroviral small molecule that appears to be a host-targeting inhibitor of HIV-1 assembly 98%
- Characterization of human immunodeficiency virus (HIV-1) envelope glycoprotein variants selected for resistance to a CD4-mimetic compound 97%
- The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity 97%
Similar papers in this journal
- Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2 96%
- Sphingosine kinases promote Ebola virus infection and can be targeted to inhibit filoviruses, coronaviruses, and arenaviruses using late endocytic trafficking to enter cells 94%
- Small-Molecule In Vitro Inhibitors of the Coronavirus Spike - ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2 94%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.